Sangamo Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on Sangamo Therapeutics Inc in one report.
- Save hours of research time and resources with
our up-to-date Sangamo Therapeutics Inc Strategy Report
- Understand Sangamo Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Sangamo Therapeutics Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Sangamo Therapeutics Insights data
Headline | Published | Journalists |
---|---|---|
Deserunt mollit sunt Lorem laborum do id aliqua dolore | 15 Mar 2019 | Lorem |
Sangamo’s Phase I SB-913 study in MPS II unlikely to see neurological disease changes but somatic manifestations have better chance, experts say | 17 Oct 2018 | Mina Moawad |
Sangamo’s gene therapy clinical development less appealing if hemophilia A trial repeats preclinical immunosuppression strategy, experts say | 16 Mar 2018 | Alaric DeArment |
Sangamo’s next trial of MPS-1 gene therapy raises design challenges around patient variability, CNS measures and control arm -- experts | 29 Jan 2018 | Fiona Barry,;Hamish McDougall |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer